The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
No Standard therapy has been approved for third-line therapy of advanced pancreatic cancer.
K001 is peptidoglycan prepared from the marine microorganism, with an anti-tumor activity.
Previously, the phase I study of K001 has shown that K001 was safety and had some
effectiveness for pancreatic patients. Now, we would like to lunch a randomized, blinded,
parallel-controlled, multi-center phase II/III study to compare the best support care (BSC)
plus K-001 versus BSC plus placebo for the third-line and later treatment of patients with
advanced pancreatic cancer.